Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation: 2024-2025

Historic Share-based Compensation for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $11.0 million.

  • Kura Oncology's Share-based Compensation rose 31.73% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $33.9 million for FY2024, which is 20.71% up from last year.
  • Latest data reveals that Kura Oncology reported Share-based Compensation of $11.0 million as of Q3 2025, which was up 57.79% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Share-based Compensation ranged from a high of $11.0 million in Q3 2025 and a low of $6.9 million during Q2 2025.
  • Its 2-year average for Share-based Compensation is $8.5 million, with a median of $8.4 million in 2024.
  • Over the last 5 years, Kura Oncology's Share-based Compensation had its largest YoY gain of 31.73% in 2025, and its largest YoY loss of 17.57% in 2025.
  • Kura Oncology's Share-based Compensation (Quarterly) stood at $8.6 million in 2024, then surged by 31.73% to $11.0 million in 2025.
  • Its Share-based Compensation was $11.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $7.8 million in Q1 2025.